http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-084262-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5b755982699e3ea5199d569ee5f5344c |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D231-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 |
| filingDate | 2011-12-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8d0e4437eb431f753b0490d3803114e6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a4b605e2be0d48264fb98defc4954de8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7931265298dc2a2ca04ca25fb84c6b7b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0a0dde521d216c4d903a1e96937fb7fc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_67c50987aeda4ccbf91d5f300935d5f2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ad076be51536dca5f33d2582bbc61359 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ed6248ecdd4242024b6c84d882668833 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6002628cb2cfd04bda582217d6347b12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c2c19919673ebb898eed56952129d00e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_79f8f31710dd056cf8f4cf7a7aaf7038 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9d00e33104faeb2e002bf25f665cb56c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_001bcd8f8bb8640d6ea58716c64c1ca8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3b95bd7afa9ab68a9e88eab9211fab53 |
| publicationDate | 2013-05-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-084262-A1 |
| titleOfInvention | SUBSTITUTED COMPOUNDS OF N- (1H-INDAZOL-4-IL) IMIDAZO [1,2-A] PIRIDIN-3-CARBOXAMIDE AS INHIBITORS OF TYPE-KINASE RECEIVING TYPE III |
| abstract | These compounds are cFMS inhibitors and are useful in the treatment of fibrosis, bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases, pain and burns in a mammal. Pharmaceutical compositions and compound preparation process are also included. Claim 1: A compound having the general formula (1) or a pharmaceutically acceptable salt thereof, wherein: R1 is hetAr1 (CH2) m-, hetAr2CH2-, hetAr3CH2- , (C3-6 cycloalkyl) -CH2-, hetCyc1CH2-, Ar1 (CH2) - or (N-C1-3alkyl) pyridinonyl-CH2-; hetAr1 is a 6-membered heteroaryl having 1-2 N ring atoms and is optionally substituted by one or more substituents independently selected from C1-6 alkyl, C1-4 alkoxy, halogen, CF3 or C3-6 cycloalkyl; m is 0, 1 or 2; hetAr2 is a 5-membered heteroaryl ring having 2-3 ring heteroatoms independently selected from N and S where at least one of said heteroatoms is N, where said ring is optionally substituted by one or more substituents independently selected from C1-6 alkyl ; hetAr3 is a 5,6-fused bicyclic heteroaryl ring having two ring nitrogen atoms; hetCyc1 is a 6-membered saturated heterocyclic ring that has 1-2 ring heteroatoms independently selected from N and O and is optionally substituted by -C (= O) (C1-6 alkyl) or -C (= O) O (alkyl C1-6); Ar1 is phenyl optionally substituted by one or more substituents independently selected from halogen, C1-6 alkyl, CN, CF3, OH, C1-6 alkoxy, -C (= O) OH, -C (= O) O (C1- alkyl 6), -C (= O) NRaRb or benzyloxy; Ra and Rb are independently H or C1-6 alkyl; n is 0, 1 or 2; R2 is H, F, Cl or CH3; R3 is H, F or Cl; R4 is H, CN, F, Cl, Br, -OMe, -OCF3, -CF3, -CH (OH) CH2OH or -C (= O) NH2; R5 is selected from: H, halogen, CN, OH, hetAr4, hetAr5, hetCyc2, hetCyc3 (C1-4 alkyl) -, hetCyc4-C1-4 alkoxy, hetCyc5-C1-4 alkoxy, (C1-3 alkoxy) C1 alkoxy -4, hydroxy-C1-6 alkoxy, dihydroxy-C2-6 alkoxy, C1-6 alkoxy, [hydroxy-C2-4amino] -C1-4 alkyl, [(C1-4 alkoxy) (C1-4 alkyl) amino ] C1-4 alkyl, [di (C1-4 alkyl) amino] C1-4 alkyl, (C1-4 alkyl) C (= O) -, hydroxy-C1-6 alkyl, dihydroxy-C2-6 alkyl, [di (C1-3 alkyl) amino] C1-4 alkoxy, N- (C1-3 alkyl) pyridinone, hetAr6, hetCyc6-C (= O), (hetCyc7) -O-, hetCyc8-C1-4 alkoxy, difluoroamine-alkoxy C1-4, [(C1-4 alkoxy) carbonylamide] C1-4 difluoroalkoxy, (C1-4 alkyl) C (= O) NH-C2-4 alkylthio, (C1-4 alkyl) OC (= O) -, or RcRdNC (= O) -; hetAr4 is a 5-membered heteroaryl ring having 1-3 ring heteroatoms independently selected from N, O and S, wherein said ring is optionally substituted by one or more substituents independently selected from C1-6 alkyl and [C1-3amino dialkyl] CH2-; hetAr5 is a 6-membered heteroaryl ring having 1-2 ring N atoms and is optionally substituted by one or more substituents independently selected from C1-6 alkyl; hetAr6 is a 9-membered partially unsaturated bicyclic heterocyclic ring having 3 ring N atoms and is optionally substituted by one or more substituents independently selected from C1-6 alkyl; hetCyc2 is a 5-7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms selected from N and O, where the ring is optionally substituted by one or more substituents independently selected from C1-6 alkyl, C1-6 hydroxyalkyl , OH and oxo, with the proviso that oxo is in a carbon atom; hetCyc3 is a 4-6 membered heterocyclic ring having 1-2 ring N atoms and is optionally substituted by one or more substituents independently selected from C1-6 alkyl, C1-6 alkoxy and halogen; hetCyc4 is a 4-7 membered heterocycle having 1-2 ring heteroatoms independently selected from N, O and S, where one of said nitrogen atoms is optionally oxidized to N (O) and where said ring S atom is optionally oxidized to SO or SO2, where hetCyc4 is optionally substituted by one or more substituents independently selected from halogen, OH, C1-6 alkyl, (C1-4 alkoxy) C1-6 alkyl, C1-4-OC alkyl (= O) - and C1-6 alkoxy; hetCyc5 is a spiro heterocycle having 2 ring heteroatoms independently selected from N and O, where hetCyc5 is optionally substituted by a group selected from C1-6 alkyl; hetAr5 is a 6-membered heterocyclic ring having 1-2 ring N atoms and is optionally substituted by one or more substituents independently selected from C1-6 alkyl; hetCyc7 is a 4-6 membered heterocyclic ring having one or two ring N atoms and is optionally substituted by one or more substituents independently selected from C1-6 alkyl and OH; hetCyc8 is a bridged 8-membered heterocyclic ring having 2 ring atoms selected from N and O where at least one of said heteroatoms is N, where said ring is optionally substituted by C1-6 alkyl; Rc is H or C1-4 alkyl; Rd is C1-4 alkyl, hetCyc10-, C1-4 aminoalkyl or [di (C1-4 alkyl) amino] C1-4 alkyl; hetCyc10 is a 5-membered heterocyclic ring having an N-ring atom and is optionally substituted by one or more substituents independently selected from C1-6 alkyl; and R6 is H or Cl. |
| priorityDate | 2011-12-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 32.